Germany: ArchiMed acquires majority stake in Cube Biotech as final deal in MED II fund

Trans-Atlantic private equity healthcare specialist, ArchiMed, has purchased a majority stake in Germany-based Cube Biotech. This investment represents the final deal in ArchiMed’s MED II fund, which raised €315m (US$364.3m) in 2017. ArchiMed will fund further acquisitions for Cube, a provider of membrane protein services for the biopharma research market, expand sales in the US…

You must be a HMI Subscriber to view this content.

Subscribe Now »